EP3833691A4 - Anticorps anti-pd-l1 humains - Google Patents
Anticorps anti-pd-l1 humains Download PDFInfo
- Publication number
- EP3833691A4 EP3833691A4 EP20796021.2A EP20796021A EP3833691A4 EP 3833691 A4 EP3833691 A4 EP 3833691A4 EP 20796021 A EP20796021 A EP 20796021A EP 3833691 A4 EP3833691 A4 EP 3833691A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- antibodies
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019084468 | 2019-04-26 | ||
PCT/CN2020/087019 WO2020216379A1 (fr) | 2019-04-26 | 2020-04-26 | Anticorps anti-pd-l1 humains |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3833691A1 EP3833691A1 (fr) | 2021-06-16 |
EP3833691A4 true EP3833691A4 (fr) | 2022-05-18 |
Family
ID=72940614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20796021.2A Pending EP3833691A4 (fr) | 2019-04-26 | 2020-04-26 | Anticorps anti-pd-l1 humains |
Country Status (14)
Country | Link |
---|---|
US (1) | US11208486B2 (fr) |
EP (1) | EP3833691A4 (fr) |
JP (1) | JP7212990B2 (fr) |
KR (1) | KR20210070323A (fr) |
CN (1) | CN112996815B (fr) |
AU (1) | AU2020261961B2 (fr) |
BR (1) | BR112021005365A2 (fr) |
CA (1) | CA3112681A1 (fr) |
EA (1) | EA202190495A1 (fr) |
IL (1) | IL281397B (fr) |
MX (1) | MX2021004897A (fr) |
SG (1) | SG11202103000WA (fr) |
WO (1) | WO2020216379A1 (fr) |
ZA (1) | ZA202101523B (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023187460A1 (fr) * | 2022-04-01 | 2023-10-05 | Mabtree Biologics Ag | Anticorps humain ou fragment de liaison à l'antigène de celui-ci spécifique contre pd-l1 pour améliorer la fonction des lymphocytes t |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010077634A1 (fr) * | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t |
WO2013079174A1 (fr) * | 2011-11-28 | 2013-06-06 | Merck Patent Gmbh | Anticorps anti-pd-l1 et utilisations associées |
WO2018178122A1 (fr) * | 2017-03-29 | 2018-10-04 | Glycotope Gmbh | Anticorps pd-l1 et ta-muc1 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6420140B1 (en) | 1996-10-11 | 2002-07-16 | Abgenix, Inc. | Production of multimeric protein by cell fusion method |
CN115093480A (zh) | 2012-05-31 | 2022-09-23 | 索伦托药业有限公司 | 与pd-l1结合的抗原结合蛋白 |
WO2014055897A2 (fr) * | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Anticorps monoclonaux humains anti pd-l1 et procédés d'utilisation |
TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
CN105777906B (zh) * | 2014-12-19 | 2019-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗pd-l1全人抗体及其应用 |
JP6983371B2 (ja) * | 2015-11-17 | 2021-12-17 | スーヂョウ サンケイディア バイオファーマスーティカルズ カンパニー リミテッド | 抗pd−l1抗体、その抗原結合フラグメントおよびその医療用途 |
CN106939047B (zh) * | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
US10590199B2 (en) | 2016-06-29 | 2020-03-17 | Checkpoint Therapeutics, Inc. | PD-L1-specific antibodies and methods of using the same |
TWI829628B (zh) * | 2016-12-19 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | 與靶向4-1bb (cd137)促效劑併用之組合療法 |
CN110856446A (zh) * | 2017-04-18 | 2020-02-28 | 阿法姆海外股份有限公司 | 抗pd-l1抗体及其用途 |
EP3649154A1 (fr) * | 2017-07-06 | 2020-05-13 | Merus N.V. | Molécules de liaison permettant de moduler l'activité biologique exprimée par une cellule |
CN111225926A (zh) * | 2017-10-10 | 2020-06-02 | 努玛治疗有限公司 | 靶向pdl1的抗体及其使用方法 |
CA3092421A1 (fr) * | 2018-03-01 | 2019-09-06 | Vrije Universiteit Brussel | Immunoglobulines se liant au pd-l1 humain |
-
2020
- 2020-04-26 JP JP2021513983A patent/JP7212990B2/ja active Active
- 2020-04-26 AU AU2020261961A patent/AU2020261961B2/en active Active
- 2020-04-26 KR KR1020217012703A patent/KR20210070323A/ko not_active Application Discontinuation
- 2020-04-26 SG SG11202103000WA patent/SG11202103000WA/en unknown
- 2020-04-26 BR BR112021005365A patent/BR112021005365A2/pt unknown
- 2020-04-26 CN CN202080005962.XA patent/CN112996815B/zh active Active
- 2020-04-26 US US17/277,909 patent/US11208486B2/en active Active
- 2020-04-26 CA CA3112681A patent/CA3112681A1/fr active Pending
- 2020-04-26 WO PCT/CN2020/087019 patent/WO2020216379A1/fr unknown
- 2020-04-26 EA EA202190495A patent/EA202190495A1/ru unknown
- 2020-04-26 EP EP20796021.2A patent/EP3833691A4/fr active Pending
- 2020-04-26 MX MX2021004897A patent/MX2021004897A/es unknown
-
2021
- 2021-03-05 ZA ZA2021/01523A patent/ZA202101523B/en unknown
- 2021-03-10 IL IL281397A patent/IL281397B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010077634A1 (fr) * | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t |
WO2013079174A1 (fr) * | 2011-11-28 | 2013-06-06 | Merck Patent Gmbh | Anticorps anti-pd-l1 et utilisations associées |
WO2018178122A1 (fr) * | 2017-03-29 | 2018-10-04 | Glycotope Gmbh | Anticorps pd-l1 et ta-muc1 |
Also Published As
Publication number | Publication date |
---|---|
CN112996815A (zh) | 2021-06-18 |
US20210309747A1 (en) | 2021-10-07 |
JP7212990B2 (ja) | 2023-01-26 |
EA202190495A1 (ru) | 2022-02-03 |
CN112996815B (zh) | 2024-02-20 |
WO2020216379A1 (fr) | 2020-10-29 |
US11208486B2 (en) | 2021-12-28 |
ZA202101523B (en) | 2022-06-29 |
AU2020261961A1 (en) | 2021-04-22 |
IL281397B (en) | 2022-04-01 |
EP3833691A1 (fr) | 2021-06-16 |
JP2022511311A (ja) | 2022-01-31 |
MX2021004897A (es) | 2021-06-18 |
KR20210070323A (ko) | 2021-06-14 |
IL281397A (en) | 2021-04-29 |
CA3112681A1 (fr) | 2020-10-29 |
AU2020261961B2 (en) | 2022-07-07 |
BR112021005365A2 (pt) | 2021-11-16 |
SG11202103000WA (en) | 2021-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3986936A4 (fr) | Anticorps anti-tigit | |
EP3880239A4 (fr) | ANTICORPS SIRPalpha THÉRAPEUTIQUES | |
EP3824096A4 (fr) | Nouveaux anticorps et leurs procédés de préparation et d'utilisation | |
EP3918323A4 (fr) | Anticorps anti-gal3 et leurs utilisations | |
EP3997127A4 (fr) | Anticorps ciblant la dll3 et leurs utilisations | |
EP3746120A4 (fr) | Anticorps anti-pd-1 | |
EP3962956A4 (fr) | Anticorps anti-hvem et leur utilisation | |
AU2019361253A1 (en) | Anti-synuclein antibodies | |
EP3962954A4 (fr) | Anticorps anti-galectine-9 et leurs utilisations | |
EP4025609A4 (fr) | Anticorps anti-steap1 et leurs utilisations | |
EP4001308A4 (fr) | Anticorps anti-tigit et leur application | |
EP3768724A4 (fr) | Nouveaux anticorps anti-pd-1 | |
EP3986462A4 (fr) | Anticorps anti-tim-3 | |
EP4029878A4 (fr) | Anticorps monoclonal humain ciblant ykl-40 | |
EP3995582A4 (fr) | Anticorps anti-epha4 | |
EP4018998A4 (fr) | Produit cosmétique | |
EP3852779A4 (fr) | Anticorps anti-klrg1 | |
EP3870222A4 (fr) | Anticorps anti-vih | |
EP3837286A4 (fr) | Anticorps dirigés contre znt8 humain | |
EP4010368A4 (fr) | Anticorps anti-nampt et leurs utilisations | |
EP4037703A4 (fr) | Formulations d'anticorps anti-connexine | |
EP3947462A4 (fr) | Anticorps anti-galectine-9 et leurs utilisations | |
EP3917965A4 (fr) | Nouveaux anticorps anti-ifnar1 | |
EP3949801A4 (fr) | Ensemble cosmétique | |
EP3829606A4 (fr) | Anticorps anti-cd79 et leurs utilisations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210312 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20220420 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 39/00 20060101ALI20220412BHEP Ipc: A61K 39/395 20060101ALI20220412BHEP Ipc: G01N 33/68 20060101ALI20220412BHEP Ipc: C12P 21/02 20060101ALI20220412BHEP Ipc: C12N 15/13 20060101ALI20220412BHEP Ipc: C07K 16/28 20060101AFI20220412BHEP |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20230418 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: I-MAB BIOPHARMA CO., LTD. |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20240409 |